Dr. Sidney P. Smith, M.D
Mohs Surgery (MOHS-Micrographic Surgery Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Georgia School of Medicine (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 2,577
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Medical College of Georgia School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
MOHS-Micrographic Surgery Physician primary
GA license 038615 -
Dermatology Physician
GA license 038615 · SC license 17623 -
Dermatopathology Physician
GA license 038615 · SC license 17623 -
Family Medicine Physician
GA license 38615 -
Internal Medicine Physician
GA license 038615 -
Pediatric Dermatology Physician
GA license 038615 · SC license 17623 -
Procedural Dermatology Physician
GA license 038615 · SC license 17623
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Roper Hospital Charleston, SC
- Bon Secours-St Francis Xavier Hospital Charleston, SC
- Roper St Francis Hospital-Berkeley Inc Summerville, SC
- St Joseph's Hospital - Savannah Savannah, GA
- Colleton Medical Center Walterboro, SC
Medical groups
- Sidney P Smith MD PC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 2,577
- Services billed
- 12,885
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Biopsy of related skin growth, each additional growth | 1,310 | 532 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,069 | 940 |
| Biopsy of related skin growth, first growth | 1,066 | 944 |
| Destruction of precancer skin growth, 2-14 growths | 931 | 214 |
| Amnioarmor, per square centimeter | 891 | 72 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 705 | 464 |
| Established patient office or other outpatient visit, 30-39 minutes | 627 | 533 |
| Destruction of precancer skin growth, 1 growth | 366 | 319 |
| Superficial and/or low voltage radiation treatment delivery | 305 | 28 |
| Removal and microscopic exam of growth of trunk, arms, or legs, 1-5 tissue blocks | 242 | 165 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 61 payments worth $1,338 in total to this clinician.
| Pfizer Inc. | $269 |
|---|---|
| Sun Pharmaceutical Industries Inc. | $253 |
| Regeneron Healthcare Solutions, Inc. | $212 |
| Janssen Biotech, Inc. | $99.00 |
| Amgen Inc. | $91.87 |
| AbbVie Inc. | $83.77 |
| Leo Pharma Inc. | $37.23 |
| E.r. Squibb & Sons, L.l.c. | $35.82 |
| Food and Beverage | $1,144 |
|---|---|
| Education | $194 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Feb 27, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
| Sun Pharmaceutical Industries Inc. Jul 19, 2025 | Education in-kind | $94.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $355,970 in research payments for these studies, mostly to the institutions running them.
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Sun Pharmaceutical Industries Inc. - TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT05769777 - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 52 weeks of treatment
Takeda Pharmaceuticals U.S.A., Inc. - Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries Inc. - A phase 3 randomized doubleblind 52WEEK placebocontrolled multicenter study with a doubleblind 52WEEK extension period with randomized dose updose down titration investigating the efficacy safety and tolerability of r…
Pfizer Inc. - A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe At…
Amgen Inc. - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
AbbVie Inc. · Active, not recruiting · NCT06389136
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.